Karyopharm leans heavily on one cancer drug just as it faces a looming debt bill and tight cash, leaving little room for surprises. The upside hinges on new uses for its drug in other cancers, but competition and tougher reimbursement rules could make that recovery harder than it looks.Read more
A small cancer-drug company could see much wider use of its main pill if late-stage trial results hold up and doctors adopt it faster than expected. But the story hinges on one medicine and the company may need fresh funding soon, making the upside and the risks unusually tied together.Read more
Karyopharm could be nearing a make-or-break moment as key late-stage cancer trial results approach, which may open the door to broader use of its lead drug and wider reach through partners overseas. But the company’s tight cash situation and heavy reliance on one product mean a setback in those trials or tougher competition could quickly change the story.Read more
No trending discussion available.
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also develops Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating other myeloproliferative neoplasms and TP53 wild-type solid tumors. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed or refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.
